Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03269344 · ClinicalTrials.gov registry record · Phase 3
Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
A Phase 3 study of Oropharynx Cancer, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT03269344 is a Phase 3 study of Oropharynx Cancer that has completed, run by Henry Ford Health System. The registered enrollment target is 65 participants, below the 130-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03269344, a Phase 3 study of Oropharynx Cancer, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
Strategies to minimize and mitigate external beam radiation therapy related mucositis and pain during the treatment of head and neck cancer remain limited. The investigators hypothesize that gabapentin could be used to delay or reduce treatment-related pain, reliance on opioid medication, and improve the quality of life for these patients.
Conditions Studied
Interventions
- DRUG Placebo Oral Capsule
- DRUG Gabapentin
Study Locations (1)
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2020-12-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03269344
The ClinicalTrials.gov registry entry for NCT03269344 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (50% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oropharynx Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT03269344 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03269344 about?
NCT03269344 is a clinical study titled "Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer". Strategies to minimize and mitigate external beam radiation therapy related mucositis and pain during the treatment of head and neck cancer remain limited. The investigators hypothesize that gabapentin could be used to delay or reduce treatment-related pain, reliance on opioid medication, and improv...
What is the current status of trial NCT03269344?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2017-06-05. Estimated completion is 2020-12-09.
What conditions does trial NCT03269344 study?
This clinical trial studies the following conditions: Oropharynx Cancer.
What interventions are being tested in trial NCT03269344?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT03269344?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03269344 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
COMPLETED · Phase 3
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
RECRUITING · Phase 2
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.